Tilsotolimod - New Trial ... | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1609 of 1650  at  2/18/2020 9:00:58 AM  by

auh2oman


Tilsotolimod - New Trial ...

Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

2020-02-17 18:20:22 | BioPortfolio

Summary

Open label, phase Ib study of intratumoral tilsotolimod in combination with intratumoral ipilimumab and intravenous nivolumab.

The trial will be divided into two parts:

PART A:

the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies

PART B:

the second part will include 3 expansion cohorts of 15 patients:

- B1: anti-PD-1 refractory advanced NSCLC cohort

- B2: anti-PD-1 refractory advanced melanoma cohort

- B3: immunotherapy naïve microsatellite stable colorectal cancer (MSS CRC) cohort

Study Design

Conditions

Advanced Cancer

Intervention

Ipilimumab, Nivolumab, Tilsotolimod

Location

Gustave Roussy
Villejuif
Val De Marne
France
94805

Status

Not yet recruiting

Source

Gustave Roussy, Cancer Campus, Grand Paris

 
 
 https://www.bioportfolio.com/resources/trial/264395/Intratumoral-Tilsotolimod-a-TLR-9-Agonist-Together-With-Intratumoral-Ipilimumab-and-Intravenous.html
 
 
 https://clinicaltrials.gov/ct2/show/NCT04270864
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 224
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1610 Re: Tilsotolimod - New Trial ... vorlon1966 1 2/24/2020 8:14:34 PM
1613 Re: Tilsotolimod - New Trial ... vorlon1966 1 2/24/2020 9:01:48 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...